Peptide therapy · Research peptide

BPC-157, a research peptide for tissue recovery, honest evidence and disclosed limits.

BPC-157 is one of the most-searched peptides on the internet, with over 300,000 monthly searches reflecting intense public interest. Most of what is published online overstates what the science shows. This page gives the unfiltered version: what animal and limited human data actually demonstrate, what the FDA's current regulatory position is, and what to expect if you pursue this therapy at Genesis Longevity in Colorado Springs.

Schedule a complimentary consultationTalk to a Provider
Healthcare professional holding a vial of BPC-157 research peptide in a modern wellness clinic setting

What it is

BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid peptide derived from a sequence in human gastric juice. It does not occur naturally in circulation at pharmacological concentrations.

BPC-157 is described as a research compound because no pharmaceutical company has completed the large-scale, placebo-controlled human trials required for FDA drug approval. This is not because it is known to be ineffective. The economics of peptide development (low cost to synthesize, limited patent protection) do not justify the investment an NDA requires. It is available in the United States only through 503A compounding pharmacies with a valid provider prescription, and that availability is subject to ongoing FDA regulatory action under the Pharmacy Compounding Advisory Committee (PCAC) review.

Mechanism descriptions in this section reflect preclinical and mechanism-of-action research. Human mechanistic studies confirming these pathways at compounded injectable doses do not exist.

How it works

In animal and cell-culture models, BPC-157 promotes angiogenesis (new blood vessel formation) via VEGFR2 signaling and nitric oxide modulation, which may support tissue perfusion at injury sites. It modulates growth hormone secretagogue receptor pathways and stabilizes intestinal tight junction proteins (claudins, occludin, ZO-1), which may explain its observed effects in gut-related applications.

BPC-157 also demonstrates neuroprotective and hepatoprotective effects in rodent models. The essential caveat: every mechanism described derives from preclinical models, primarily cell cultures and rodents. Whether animal-model biology translates to meaningful clinical outcomes in humans is the central unanswered question.

On human evidence specifically: two small Croatian clinical trials in the early 2000s tested BPC-157 in ulcerative colitis patients and reported safety and possible efficacy signals. One pilot pharmacokinetic and safety study conducted intravenous BPC-157 in two healthy human volunteers. A 2025 systematic review of BPC-157 for musculoskeletal injuries concluded the peptide "shows promise" based on animal data but emphasized the complete absence of human safety or efficacy data for that indication. For tendon, ligament, rotator cuff, Achilles, or plantar fasciitis claims, there are no human RCTs.

Conditions and use cases

Where BPC-157 may have a role at Genesis Longevity.

  • Acute or chronic soft-tissue injuries (tendinopathy, partial tears, post-surgical recovery) that have not responded to conventional care including physical therapy, NSAIDs, or corticosteroid management.
  • Post-surgical recovery seeking adjunctive support, after a documented procedure with surgeon clearance.
  • Inflammatory bowel symptoms based on the Croatian colitis data, requiring a provider GI workup first and gastroenterology co-management.
  • Not appropriate as first-line therapy or as a substitute for surgery. Patients should have a documented injury with prior conservative management and understand the experimental status.

Expected timeline

What patients commonly observe.

  1. Week 0 to 2

    Onset signals

    Anecdotal protocols report early reduction in localized pain in acute soft-tissue injury contexts. Injection-site induration is common.

  2. Week 2 to 4

    Subjective benefit

    TB-500 paired protocols often report reduced inflammation and improved mobility in this window. Individual response is highly variable.

  3. Month 1 to 3

    Course window

    Typical compounded courses run 4 to 12 weeks at 250 to 500 mcg subcutaneous daily. Provider review at 4 weeks.

  4. Month 3 to 6

    Reassess and pause

    Long-term safety beyond approximately 12 weeks is unknown in humans. Provider reviews response and pauses or cycles per protocol.

Stacks that include this therapy

BPC-157 appears in these stacks.

Investment and access

Care plans, not menus.

Genesis Longevity therapies are dispensed only after a complimentary consultation and Good Faith Exam. Schedule yours to receive a personalized plan tailored to your biology and goals.

Schedule a complimentary consultationRequest a custom plan

Side effects

What patients commonly report.

Reported anecdotally and in the limited human data: injection site reactions including induration and nodule formation; dizziness and lightheadedness; mild GI upset; headache; rare tachycardia in TB-500 paired protocols.

Long-term safety beyond approximately 12 weeks is unknown in humans. This is not a theoretical concern. It is a genuine data gap.

Contraindications

Who should not use this therapy.

Show contraindications

Absolute contraindications. Active malignancy (BPC-157 is pro-angiogenic; theoretical support of tumor vascularity, not documented in humans). Pregnancy and breastfeeding (no safety data). Known hypersensitivity to the peptide.

Relative contraindications requiring shared decision-making. Personal history of cancer (no long-term oncologic surveillance data; specialist clearance recommended). Immunosuppression (theoretical immune modulation effects). Current anticoagulation therapy (angiogenic pathways may interact). Age under 18 (no pediatric data).

Competitive athletes subject to WADA testing. BPC-157 is on the WADA Prohibited List. Discuss your sport-testing requirements with your provider before any compounded peptide.

Pairs well with

Therapies that complement this protocol.

Frequently asked

Frequently asked questions about BPC-157.

Sources

Citations & references

  1. [1]BPC-157 pharmacokinetics and safety (pilot IV study, n=2). PubMed 40131143.
  2. [2]Lengea Law, FDA peptide 503A review: BPC-157 and TB-500. Source
  3. [3]FDA Pharmacy Compounding Advisory Committee, July 2026 meeting. Source
  4. [4]SSRP Institute, FDA announces change in status of 12 peptides. Source
  5. [5]Systematic review: BPC-157 for orthopedic and musculoskeletal injuries (Sage, 2025). Source
  6. [6]Peptide Biologix, TB-500 / Thymosin Beta-4 overview. Source
  7. [7]Pulse and Remedy, BPC-157 + TB-500 combination in concierge medicine. Source
  8. [8]Clinical Trial NCT02637284, BPC-157 phase I registered trial. Source

Status & disclosures

FDA status: research peptide, not FDA-approved
BPC-157 is not an FDA-approved drug. Its compounding status under 503A pharmacy regulations is under active FDA Pharmacy Compounding Advisory Committee (PCAC) review. Availability may change based on regulatory outcomes. Repeated visibly per template requirement: not FDA-approved.
503A compounded preparation
Compounded medications are prepared by licensed 503A pharmacies under U.S. FDA regulations. Genesis sources from regulated pharmacies that follow USP standards.
WADA prohibited
BPC-157 appears on the World Anti-Doping Agency Prohibited List. Athletes subject to WADA testing should not use this therapy.
Experimental status, informed consent required
Use of BPC-157 at Genesis Longevity requires informed consent acknowledging the experimental nature of the therapy and the absence of human RCT data for musculoskeletal indications.
Provider supervision and Good Faith Exam
Therapy requires a Good Faith Exam and provider consultation. Educational information on this page is not medical advice.

Next step

Talk to a Genesis provider about BPC-157.

Schedule a consultation. Physician-led, evidence-graded.

Book a ConsultationTalk to a Provider

Or keep reading: See the Restore & Recover stack